EuroPCR 2021 | TVT Registry: Outcomes of TAVR in Low Surgical Risk Bicuspids

In bicuspid patients with aortic stenosis and low surgical risk, transcatheter aortic valve replacement (TAVR) with balloon expandable valve offers results comparable to normal anatomy results.  These data come from the TVT registry, presented at EuroPCR 2021 scientific sessions. Stroke and death rates (inhospital, 30 days and one year) in bicuspid patients did not result<a href="https://solaci.org/en/2021/05/27/europcr-2021-tvt-registry-outcomes-of-tavr-in-low-surgical-risk-bicuspids/" title="Read more" >...</a>

ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR

Indicating apixaban after transcatheter aortic valve replacement (TAVR) does not significantly reduce the risk of sub-clinical leaflet thrombosis compared with the standard of care. These data come from the computerized tomography (CT) scan sub-study from ATLANTIS, presented during the scientific sessions of the American College of Cardiology (ACC) 2021 Congress. In patients with no prior<a href="https://solaci.org/en/2021/05/19/acc-2021-atlantis-4d-ct-apixaban-and-sub-clinical-thrombosis-after-tavr/" title="Read more" >...</a>

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard antithrombotic treatment, according to the randomized ATLANTIS trial presented today at the American College of Cardiology (ACC) 2021 Congress. Given its easy indication and good safety profile, it could be an option to vitamin K antagonists for patients with<a href="https://solaci.org/en/2021/05/18/acc-2021-atlantis-apixaban-after-tavr-vs-standard-of-care/" title="Read more" >...</a>

Is Rheumatic Etiology Counter Indicated for TAVR?

Patients with rheumatic aortic stenosis have been systematically excluded from all studies on transcatheter aortic valve replacement (TAVR).  This study compared TAVR vs surgical aortic valve replacement (SAVR) outcomes in patients with rheumatic aortic stenosis and also vs TAVR outcomes in patients with degenerative aortic stenosis.  The study looked at rheumatic aortic stenosis patients receiving<a href="https://solaci.org/en/2021/05/17/is-rheumatic-etiology-counter-indicated-for-tavr/" title="Read more" >...</a>

Validating Consensus on Post TAVR Conduction Disturbances in the Clinical Practice

Little over a year ago, JACC published the expert consensus on the management of post transcatheter aortic valve replacement (TAVR) conduction disturbances. This publication homogenized criteria and was welcomed by operators who, when in doubt, tended to prematurely indicate definite pacemaker implantation or delayed discharge in order to monitor patients.  These criteria, however, was nothing<a href="https://solaci.org/en/2021/05/12/validating-consensus-on-post-tavr-conduction-disturbances-in-the-clinical-practice/" title="Read more" >...</a>

Most read scientific articles of april at solaci.org

The most read scientific articles on interventional cardiology of april

01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration.  Read more HERE 02- Thrombocytopenia and Thrombosis May Be Linked to AstraZeneca Vaccine, Analysis Reports This is one of the<a href="https://solaci.org/en/2021/05/07/the-most-read-scientific-articles-on-interventional-cardiology-of-april/" title="Read more" >...</a>

Incidence, Predictors, and Results of Acute Kidney Injury in Patients Undergoing TAVR

Acute kidney injury after transcatheter aortic valve replacement (TAVR) is a well-known adverse event for all interventional cardiologists. However, it has been understudied: only small observational research has been conducted, showing too wide incidence rates. This research included all patients who underwent TAVR in the USA between 2016 and 2018, totaling over 100,000 patients. All subjects<a href="https://solaci.org/en/2021/05/03/incidence-predictors-and-results-of-acute-kidney-injury-in-patients-undergoing-tavr/" title="Read more" >...</a>

duración terapia de doble antiagregación plaquetaria

Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines.  Clinical studies that investigated single antiplatelet therapy versus DAPT until November 2020 were analyzed and divided according to<a href="https://solaci.org/en/2021/04/26/dual-antiplatelet-therapy-and-tavr-obsolete-guidelines/" title="Read more" >...</a>

Cerebral Protection Devices during TAVR in the Daily Practice

The theory behind the use of cerebral protection devices during TAVR is good, but hard to test. The daily practice provides a far bigger number of patients, and therefore might be able to better show how to prevent one of the hardest events during TAVR.  This study resorted to Germany’s TAVR database between 2015 and<a href="https://solaci.org/en/2021/04/21/cerebral-protection-devices-during-tavr-in-the-daily-practice/" title="Read more" >...</a>

Es un hecho: la protección cerebral en TAVI logró demostrar que reduce el stroke y la muerte

Silent Stroke During TAVR and Early Cognitive Impairment

Silent stroke is common after transcatheter aortic valve replacement (TAVR). Co-morbidities such as diabetes or chronic renal failure, as well as procedural factors such as pre-dilation, increase the risk of silent stroke. While many events of silent stroke have an early effect on cognition, it is necessary to learn whether the impairment is sustained over<a href="https://solaci.org/en/2021/04/14/silent-stroke-during-tavr-and-early-cognitive-impairment/" title="Read more" >...</a>